Veerhealth Care secures Rs 10.07 lakh oral care order from domestic entity
- Veerhealth Care secured a new order worth Rs 10.07 lakh for oral care products from a domestic entity.
- The order requires execution within 45 days and was disclosed on September 9, 2026.
- Q2FY27 order inflows reached Rs 1133.47 crore, up from Rs 149.05 crore in Q1FY27.
- The company reports zero consolidated revenue and net profit for the trailing twelve months.
- Valuation metrics show a P/E of 64.9x against an ROCE of 2.55% as of September 11, 2026.

*this image is generated using AI for illustrative purposes only.
WHAT HAPPENED
Veerhealth Care has received a confirmed order valued at Rs 10.07 lakh from a domestic entity for the supply of oral care products. The order was disclosed to the exchange on September 9, 2026.
ORDER IN FINANCIAL CONTEXT
The Rs 10.07 lakh order value cannot be meaningfully benchmarked against average quarterly revenue, as the pre-computed average quarterly revenue is Rs 0.0 crore based on TTM data. Consequently, the book-to-bill ratio remains mathematically undefined due to zero denominator revenue. This disparity highlights that while order inflow is active, revenue recognition has not yet commenced or reported at scale.
COMPANY ORDER TRACK RECORD
Order inflow velocity has accelerated in the latest quarter. Q2FY27 saw total inflows of Rs 1133.47 crore, a sharp increase from Rs 149.05 crore in Q1FY27. The company has now received orders from multiple entity types, including domestic, international, and entities not disclosed as per confidential terms.
| Quarter | Total Order Inflow (Rs Cr) | Key Awarding Entities |
|---|---|---|
| Q2FY27 (Jul-Sep 2026) | 1133.47 | Domestic, Not disclosed as per confidential terms, one of India's leading FMCG company |
| Q1FY27 (Apr-Jun 2026) | 149.05 | Not disclosed as per confidential terms |
ORDER HISTORY
| Order Date | Order Value | Awarding Entity | Terms |
|---|---|---|---|
| 09 Sep 2026 | Rs 10.07 lakh | Not disclosed as per confidential terms | Supply of oral care products; execute within 45 days |
| 02 Sep 2026 | Rs 436.99 lakh | Not disclosed as per confidential terms | Supply of face care products; execute within 45 days |
| 04 Aug 2026 | Rs 526.84 lakh | Domestic | Supply of face care products |
| 23 Jul 2026 | Rs 76.4 lakh | One of India's leading FMCG company | New sample order for supply of skin care products under a new MRP structure for brand promotion and market expansion |
| 24 Jul 2026 | Rs 15.73 lakh | Not disclosed as per confidential terms | Supply of gripe water |
| 22 Jul 2026 | Rs 76.4 lakh | Not disclosed as per confidential terms | Supply of skincare products, contract manufacturing order under a new MRP structure for brand promotion and market expansion |
| 11 Jul 2026 | Rs 1.11 crore | Not disclosed as per confidential terms | Supply of haircare and oral care products |
| 15 May 2026 | Rs 2.45 crore | Not disclosed as per confidential terms | Supply of face care products; execute within 45 days |
| 29 Apr 2026 | Rs 143.0 lakh | Not disclosed as per confidential terms | FOB Nhava seva, supply of body care products |
| 09 Jun 2026 | Rs 3.6 crore | Not disclosed as per confidential terms | Supply of face care products |
EXECUTION AND REVENUE QUALITY
The company reports zero consolidated revenue, net profit, and operating profit margin for the trailing twelve months. This indicates that existing backlogs are not currently converting to recognized revenue in the audited financials provided.
| Period | Revenue (Rs Cr) | Net Profit (Rs Cr) | OPM (%) |
|---|---|---|---|
| TTM | 0.0 | 0.0 | 0.0% |
WORKING CAPITAL AND EXECUTION CAPACITY
Balance sheet and cashflow data are not explicitly provided in the input for detailed liquidity analysis. With zero operating cashflow and zero revenue, the company's ability to fund working capital for the existing backlog depends entirely on external financing or promoter support. The absence of reported liabilities or equity figures prevents a precise current ratio assessment, but the lack of revenue generation poses a fundamental working capital constraint until orders begin converting to billings.
WHAT TO WATCH
- Execution rate: Quarterly revenue run-rate vs total backlog is currently zero; watch for the first instance of revenue recognition to validate execution capability.
- Margin quality: OPM trajectory on new orders vs historical average is unobservable; initial revenue filings will reveal whether these contracts carry healthy margins.
- Client concentration: A significant portion of the order book comes from entities listed as "Not disclosed as per confidential terms," making it difficult to assess true client concentration risk beyond the named partners.
- Revenue recognition lag: The gap between Rs 1133.47 crore in recent order inflows and Rs 0.0 crore in TTM revenue requires monitoring to ensure orders are translating into billable milestones.
- Entity diversity: Veerhealth Care has now received orders from domestic, international, and undisclosed counterparties across the last two fiscal quarters.
KEY OBSERVATIONS
- Valuation check (as of 11 Sep 2026): P/E of 64.9x against ROCE of 2.55%. Valuation is pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
- Backlog signal: Book-to-bill is undefined due to zero TTM revenue. At this level, execution capacity becomes the binding constraint, as the entire order book must be converted to revenue to justify current market expectations.
Historical Stock Returns for Veerhealth Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.20% | -0.02% | +2.36% | +150.03% | +173.71% | +412.62% |


































